Bioverativ Therapeutics Inc. Sustainability Profile
Bioverativ Therapeutics Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for patients with rare blood disorders. Founded in 2017, Bioverativ has quickly established itself in the biopharmaceutical industry, particularly in the areas of haemophilia and other blood-related conditions. The company’s core products, including its advanced therapies for haemophilia A and B, are distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Bioverativ's dedication to research and development has positioned it as a key player in the market, achieving significant milestones in clinical trials and product launches. With a strong emphasis on patient-centric solutions, Bioverativ continues to make strides in transforming the treatment landscape for individuals with bleeding disorders.
DitchCarbon Score
How does Bioverativ Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioverativ Therapeutics Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioverativ Therapeutics Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sanofi, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Bioverativ follows initiatives set by Sanofi, which include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These initiatives aim to promote transparency and accountability in carbon emissions reduction and sustainability efforts. While specific reduction targets or achievements for Bioverativ are not detailed, the alignment with Sanofi's broader climate commitments suggests a focus on reducing emissions across all scopes. The absence of direct emissions data highlights the need for ongoing efforts in climate action and transparency within the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bioverativ Therapeutics Inc.'s Industry?
How Carbon Intensive is Bioverativ Therapeutics Inc.'s Location?
Bioverativ Therapeutics Inc.'s Scope 3 Categories Breakdown
Bioverativ Therapeutics Inc.'s Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Bioverativ Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bioverativ Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
